KPT-330 has antitumour activity against non-small cell lung cancer.
about
Mechanisms of Nuclear Export in Cancer and Resistance to ChemotherapyLongitudinal tracking of single live cancer cells to understand cell cycle effects of the nuclear export inhibitor, selinexor.Macromolecular transport between the nucleus and the cytoplasm: Advances in mechanism and emerging links to disease.Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compoundsSelective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic CancerPreclinical activity of selinexor, an inhibitor of XPO1, in sarcomaTreatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitorsMolecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma.Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents.Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin.Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia.Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer.Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin.Selective Inhibitors of Nuclear Export (SINE) compounds block proliferation and migration of triple negative breast cancer cells by restoring expression of ARRDC3.Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration.Therapeutic Targeting of Nuclear Export Inhibition in Lung Cancer.Nuclear Export Inhibition for Pancreatic Cancer Therapy.XPO1 inhibition by selinexor induces potent cytotoxicity against high grade bladder malignancies
P2860
Q26764837-59753F80-C389-48DD-A663-3D8321D5DEE6Q30665952-D7D77F3F-1B2D-41FE-91D3-72CAF5CF493DQ34169454-4796A863-0AFE-414E-A96E-B5996A2F3B7EQ35843010-A66EA6AD-A8CD-44F4-97F9-5D033020F899Q36078792-1427813B-37CC-45E8-B6DA-0835D78C61E7Q37086082-372E5B2C-73EC-49A9-A4F7-65DEDA9215AEQ37203487-E93A1DA8-6AEB-43C5-92DA-B50C2933074BQ37702556-28DB0A53-FC7A-46A6-B5AD-6860B444072CQ38260357-3D6D0D5D-524C-44A9-B718-4754FF2E8801Q38878268-F97738E5-9412-43F9-B3D6-9495A5503B18Q41087485-755825F6-D99D-4496-B0EF-ADB763772785Q41412563-CE8D8B1B-3F27-41D6-B7F7-37255DF86EBBQ41550563-DD6156C8-D6F2-4D12-AE01-FA736745E7D3Q41592977-26B17306-0031-4FCC-9284-8122CD923168Q43907188-DDAA8F31-C63C-4862-89BB-9D70778AC409Q48743003-017B4C62-9E98-43AC-8E8C-9C94B495F4C0Q55040338-39E10A32-FB18-46C1-BEAA-21BB48B8F802Q57818336-E4F3E0CA-6CC5-4755-B7CE-8F8E68F32BBC
P2860
KPT-330 has antitumour activity against non-small cell lung cancer.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
KPT-330 has antitumour activity against non-small cell lung cancer.
@ast
KPT-330 has antitumour activity against non-small cell lung cancer.
@en
type
label
KPT-330 has antitumour activity against non-small cell lung cancer.
@ast
KPT-330 has antitumour activity against non-small cell lung cancer.
@en
prefLabel
KPT-330 has antitumour activity against non-small cell lung cancer.
@ast
KPT-330 has antitumour activity against non-small cell lung cancer.
@en
P2093
P2860
P356
P1476
KPT-330 has antitumour activity against non-small cell lung cancer.
@en
P2093
G L E-Ling
H P Koeffler
M Kauffman
T Nakamaki
P2860
P2888
P304
P356
10.1038/BJC.2014.260
P407
P577
2014-06-19T00:00:00Z
P5875
P6179
1021414396